Klinische Notizen zu medizinischen Codes. KI-basiert. Kostenlos.

MedAPI.ai ist ein KI-gestützter Dienst für medizinisches Coding — per Websuche und REST-API. Gedeckte Vorschläge aus offiziellen Systematik-Inhalten, validiert gegen die autoritative Datenbank.

Codierungssysteme

Semantisches RAG-Retrieval, gedeckte Code-Vorschläge mit Confidence-Werten und Validierung gegen die autoritative Datenbank — über die unterstützten Codierungssysteme hinweg.

API

POST /api/code und GET /api/describe — Integration in KIS, Abrechnung und Forschung.

Z12.4

ICD-10-CM 2027 · Abrechenbar

Encounter for screening for malignant neoplasm of cervix

Geschwistercodes

  • Z12.0 – Encounter for screening for malignant neoplasm of stomach
  • Z12.1 – Encounter for screening for malignant neoplasm of intestinal tract
  • Z12.2 – Encounter for screening for malignant neoplasm of respiratory organs
  • Z12.3 – Encounter for screening for malignant neoplasm of breast
  • Z12.5 – Encounter for screening for malignant neoplasm of prostate
  • Z12.6 – Encounter for screening for malignant neoplasm of bladder
  • Z12.7 – Encounter for screening for malignant neoplasm of other genitourinary organs
  • Z12.8 – Encounter for screening for malignant neoplasm of other sites
  • Z12.9 – Encounter for screening for malignant neoplasm, site unspecified

Excludes1

  • when screening is part of general gynecological examination (Z01.4-)

Excludes2

  • encounter for screening for human papillomavirus (Z11.51)

Inclusion terms

  • Encounter for screening pap smear for malignant neoplasm of cervix

Vererbt von Z12: Encounter for screening for malignant neoplasms

Excludes1

  • encounter for diagnostic examination-code to sign or symptom

Inclusion terms

  • Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.

Use additional code

  • code to identify any family history of malignant neoplasm (Z80.-)

Teil von: Z12: Encounter for screening for malignant neoplasms